Securing Regulatory Foothold in the European Market

The European Medicines Agency (EMA) has granted final approval for Apixaban Accord, the generic version of the direct oral anticoagulant (DOAC) from Accord Healthcare. This approval is based on bioequivalence studies demonstrating its similarity to the original drug, Eliquis, co-marketed by BMS and Pfizer. With proven safety and efficacy, Apixaban Accord now has the regulatory foundation for legal distribution and prescription within the European Union. This marks a significant step, as it introduces a more affordable generic alternative into the anticoagulant market, previously dominated by global pharmaceutical companies.

Expanding Indications and Ensuring Clinical Utility

Apixaban Accord has received approval for multiple indications, including the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). It is also indicated for the treatment and prevention of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the prevention of venous thromboembolism (VTE) in adult patients undergoing hip or knee replacement surgery. Targeting Factor Xa inhibition, Apixaban Accord offers clinical advantages over warfarin, including the elimination of the need for routine blood monitoring and reduced drug-food interactions. These clinical benefits are expected to rapidly increase its adoption among healthcare professionals and patients in Europe.

Competitive Landscape with the Blockbuster Original, Eliquis

Eliquis, the original drug, achieved global sales of approximately $16.7 billion in 2021, making it a leading blockbuster medication. Despite intense competition from Bayer's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana (edoxaban), which share the market for thrombosis treatment, Eliquis has maintained the largest market share. Apixaban Accord is now poised to disrupt the market by offering the same efficacy as the original at a competitive price. This will undoubtedly provide an attractive alternative for European healthcare systems and patients who were previously burdened by the high cost of the original medication.

Transformation of the European DOAC Market and Financial Impact

The global DOAC market, including Europe, is rapidly expanding, reaching approximately $30 billion in 2021. The entry of Accord Healthcare's generic will intensify price pressure in the anticoagulant market, which has historically been dominated by high-priced therapies. This will also provide significant social benefits by reducing healthcare expenditure for EU member states and improving patient access to essential medications. With patent expiration and the subsequent launch of generics, competition among established players and generic manufacturers is expected to intensify.

Mid- to Long-Term Commercial Prospects of Generic Launch

This approval, finalized on July 23, 2020, represents a crucial milestone in diversifying the supply chain within the European market. While the generic launch in the US market has been delayed until after 2026 due to patent litigation, Europe is entering a generic competition phase much earlier. Accord Healthcare plans to leverage its robust sales network across Europe to rapidly gain market share. Investors should closely monitor the impact of this generic launch on the pricing dynamics and market share shifts within the European anticoagulant market.